Genetic Engineering & Biotechnology News reports Spark Therapeutics shareholders are holding back and not agreeing to sell in sufficient numbers.  Hence Roche has made a second offer. Apparently, the $4.8 billion wasn’t sufficient for Spark shareholders.  At...